Smith & Nephew SNATS (NYSE:SNN) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN – Free Report) from a buy rating to a strong-buy rating in a research report released on Sunday morning.

A number of other equities analysts have also commented on SNN. Canaccord Genuity Group reduced their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Royal Bank Of Canada restated an “outperform” rating on shares of Smith & Nephew SNATS in a research report on Monday, October 20th. Finally, Sanford C. Bernstein set a $37.50 target price on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $35.75.

Get Our Latest Stock Analysis on SNN

Smith & Nephew SNATS Stock Performance

NYSE:SNN opened at $32.30 on Friday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 1 year low of $23.69 and a 1 year high of $38.79. The firm has a 50 day moving average of $34.29 and a 200-day moving average of $33.76.

Institutional Trading of Smith & Nephew SNATS

Several institutional investors and hedge funds have recently made changes to their positions in SNN. Bank of Montreal Can increased its holdings in Smith & Nephew SNATS by 321.6% in the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after purchasing an additional 2,616,301 shares during the last quarter. River Road Asset Management LLC boosted its holdings in Smith & Nephew SNATS by 9.3% during the second quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock worth $97,175,000 after buying an additional 270,480 shares during the last quarter. Scharf Investments LLC grew its position in shares of Smith & Nephew SNATS by 0.3% during the 2nd quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock worth $63,818,000 after buying an additional 6,993 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after acquiring an additional 583,809 shares during the last quarter. Finally, Armistice Capital LLC raised its position in shares of Smith & Nephew SNATS by 258.1% in the 1st quarter. Armistice Capital LLC now owns 1,769,000 shares of the medical equipment provider’s stock valued at $50,187,000 after acquiring an additional 1,275,000 shares during the period. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

(Get Free Report)

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Further Reading